Cargando…

Etanercept in juvenile idiopathic arthritis: Who will benefit?

Detalles Bibliográficos
Autores principales:	Otten, MH, Prince, FHM, Armbrust, W, ten Cate, R, Hoppenreijs, EPAH, Twilt, M, Koopman-Keemink, Y, Gorter, SL, Dolman, KM, Swart, JF, van den Berg, JM, Wulffraat, NM, van Rossum, MAJ, van Suijlekom-Smit, LWA
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194423/ http://dx.doi.org/10.1186/1546-0096-9-S1-O28

Ejemplares similares

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis
por: Prince, FHM, et al.
Publicado: (2008)

Development of a web-based register for the Dutch national study on biologicals in juvenile idiopathic arthritis: http://www.abc-register.nl
por: Prince, FHM, et al.
Publicado: (2008)

PReS-FINAL-2146: Trends in prescription of biologics and outcomes of juvenile idiopathic arthritis; results of the Dutch national arthritis and biologicals in children register
por: Otten, MH, et al.
Publicado: (2013)

Long term functional outcome and quality of life of patients with refractory juvenile idiopathic arthritis treated with etanercept: results of the dutch arthritis and biologicals in children register
por: Anink, Janneke, et al.
Publicado: (2014)

PReS-FINAL-2145: MRP8/14 serum complexes as predictor of response to etanercept treatment in juvenile idiopathic arthritis
por: Anink, J, et al.
Publicado: (2013)

Parental preferences for treatment: Preliminary report from a randomised comparison of treatment strategies in (early) juvenile idiopathic arthritis (BeSt for Kids trial)
por: Muller, PCE Hissink, et al.
Publicado: (2011)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
por: Swart, JF, et al.
Publicado: (2013)

Association of the CD226 (DNAM-1) Gly307Ser polymorphism with juvenile idiopathic arthritis
por: Reinards, THCM, et al.
Publicado: (2011)

Association of the CCR5Δ32 variant with juvenile idiopathic arthritis in a meta-analysis
por: Reinards, THCM, et al.
Publicado: (2011)

The role of etanercept in juvenile dermatomyositis (JDMS) in children
por: Green, Katherine L, et al.
Publicado: (2014)

MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis
por: Anink, Janneke, et al.
Publicado: (2015)

A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study
por: Hissink Muller, P. C. E., et al.
Publicado: (2017)

Significant pain decrease in children with non-systemic Juvenile Idiopathic Arthritis treated to target: results over 24 months of follow up
por: Spekking, Katinka, et al.
Publicado: (2023)

Bone health assessment of patients with juvenile idiopathic arthritis: a comparison between DXA and bonexpert
por: Nusman, Charlotte M, et al.
Publicado: (2014)

Impact of orientation specific surround modulation and tuning curve shape on population coding and tilt illusion in V1
por: Keemink, Sander W, et al.
Publicado: (2013)

Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis
por: Albers, HM, et al.
Publicado: (2008)

No radiographic wrist damage after treatment to target in recent-onset juvenile idiopathic arthritis
por: Hissink Muller, P. C. E., et al.
Publicado: (2019)

2.5 Mesenchymal Stem Cell Therapy has significant clinical effect in proteoglycan induced arthritis
por: Swart, JF, et al.
Publicado: (2008)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Beukelman, Timothy, et al.
Publicado: (2021)

Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
por: van Vollenhoven, Ronald F, et al.
Publicado: (2003)

Real-world comparison of the effects of etanercept and adalimumab on well-being in non-systemic juvenile idiopathic arthritis: a propensity score matched cohort study
por: van Straalen, Joeri W., et al.
Publicado: (2022)

Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use
por: van Straalen, Joeri W, et al.
Publicado: (2021)

Etanercept biosimilars
por: Azevedo, Valderilio F., et al.
Publicado: (2014)

Illness script development in pre-clinical education through case-based clinical reasoning training
por: Keemink, Yvette, et al.
Publicado: (2018)

Factors associated with care- and health-related quality of life of caregivers of children with juvenile idiopathic arthritis
por: Grazziotin, Luiza R., et al.
Publicado: (2022)

Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial
por: Emery, Paul, et al.
Publicado: (2020)

PReS-FINAL-2160: Intestinal microbiome in polyarticular juvenile idiopathic arthritis: a pilot study
por: Hissink Muller, PC, et al.
Publicado: (2013)

Design and acceptance of Rheumates@Work, a combined internet-based and in person instruction model, an interactive, educational, and cognitive behavioral program for children with juvenile idiopathic arthritis
por: Armbrust, Wineke, et al.
Publicado: (2015)

Treatment of LADA With Etanercept
por: Montes, Vince N., et al.
Publicado: (2012)

Etanercept-associated myelitis
por: Finke, Carsten, et al.
Publicado: (2015)

Etanercept-associated Nephropathy
por: Ammar, Awais, et al.
Publicado: (2019)

Etanercept in axial spondyloarthritis
por: Luo, Gui, et al.
Publicado: (2022)

Observational study of inflammatory arthritis treatment by etanercept originator switched to an etanercept biosimilar
por: Felis-Giemza, Anna, et al.
Publicado: (2019)

Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
por: Meijboom, Rosanne W., et al.
Publicado: (2021)

PReS-FINAL-2116: Assessment of disease activity by patients with juvenile idiopathic arthritis and the parents compared to the assessment by pediatric rheumatologists
por: Armbrust, W, et al.
Publicado: (2013)

Automated determination of bone age and bone mineral density in patients with juvenile idiopathic arthritis: a feasibility study
por: Anink, Janneke, et al.
Publicado: (2014)

Patterns of clinical joint inflammation in juvenile idiopathic arthritis
por: Heckert, Sascha L, et al.
Publicado: (2023)

Etanercept in the treatment of rheumatoid arthritis
por: Haraoui, Boulos, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_g5auutavf70nca0fddfrhi4r0j